HPV Transmission: Risks, Symptoms, and Prevention

Human papillomavirus (HPV) is the most common STI globally. Nearly all sexually active people acquire it at some point.

Transmission

• Vaginal, anal, oral sex; genital skin-to-skin contact (condoms reduce but don't eliminate risk).
• Vertical (mother-to-infant) during delivery (rare, causes recurrent respiratory papillomatosis).
• Fomite transmission theoretically possible but not epidemiologically significant.

Clinical Outcomes

• Low-risk types (6, 11): Genital warts (condylomata acuminata); recurrent respiratory papillomatosis.
• High-risk types (16, 18, 31, 33, 45, 52, 58...): Cervical, vaginal, vulvar, anal, penile, oropharyngeal cancers. Most infections clear spontaneously in 1–2 years; persistence → precancer → cancer over decades.

Prevention

• Vaccination: 9vHPV (Gardasil 9) covers 7 high-risk + 2 low-risk types. Routine at 11–12 years (can start 9); catch-up to 26; shared decision-making 27–45. 2-dose (if <15) or 3-dose series.
• Condoms: Partial protection.
• Screening: Cervical cytology (Pap) + HPV co-testing per guidelines (e.g., q5y 25–65).
• Treatment of warts/precancers: Topical, ablative, excisional.

Key Message

HPV is ubiquitous; vaccination is the most powerful tool to prevent cancer. Most infections are transient; persistence drives malignancy. Regular screening catches precancer early.